Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 3
2005 3
2006 2
2010 1
2011 1
2013 2
2014 1
2018 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
The Development of a Minority Recruitment Plan for Cancer Clinical Trials.
Trevino M, Padalecki S, Karnad A, Parra A, Weitman S, Nashawati M, Pollock BH, Ramirez A, Thompson IM. Trevino M, et al. Among authors: weitman s. J Community Med Health Educ. 2013 Sep 1;3(5):1000230. doi: 10.4172/2161-0711.1000230. J Community Med Health Educ. 2013. PMID: 25152846 Free PMC article.
An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011.
Rowe J, Patel S, Mazo-Canola M, Parra A, Goros M, Michalek J, Kelly K, Weitman S, Karnad A. Rowe J, et al. Among authors: weitman s. J Geriatr Oncol. 2014 Jan;5(1):65-70. doi: 10.1016/j.jgo.2013.08.005. Epub 2013 Sep 18. J Geriatr Oncol. 2014. PMID: 24484720 Free PMC article.
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK. Mita AC, et al. Among authors: weitman s. Clin Cancer Res. 2006 Sep 1;12(17):5207-15. doi: 10.1158/1078-0432.CCR-06-0179. Clin Cancer Res. 2006. PMID: 16951240 Clinical Trial.
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr. Cunningham C, et al. Among authors: weitman s. Clin Cancer Res. 2005 Nov 1;11(21):7825-33. doi: 10.1158/1078-0432.CCR-05-0058. Clin Cancer Res. 2005. PMID: 16278405 Clinical Trial.
19 results